**Supplementary** **Table 1.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Antiretroviral agent** | **Arm A****Ibalizumab****15 mg/kg (n=28)** | **Arm B****Ibalizumab****10 mg/kg (n=27)** |  |  **Placebo Arm** **(n=27)** |
|  | OBR1 | All regimens | OBR1 | All regimens |  | OBR1 | Allregimens |
| NRTIAbacavirDidanosineEmtricitabineLamivudine StavudineTenofovirZidovudine | 7 (25) 10 (36)14 (50)5 (18)2 (7)18 (64)4 (14) |  9 (32) 11 (39) 14 (50) 8 (29) 2 (7)20 (71) 5 (18) | 5 (19)4 (15)10 (37)9 (33)2 (7)21 (78)7 (26) | 6 (21)7 (26)12 (44)11 (41)3 (11)22 (81)9 (33) | 2 (7)10 (37)11 (41)7 (26)0 (0)20 (74)5 (19) | 3 (11)11 (41)11 (41)11 (41)2 (7)20 (74)5 (19) |
| NNRTIDelavirdineEfavirenzNevirapine | 1 (4) 2 (7)0 (0) |  1 (4) 3 (11) 0 (0) | 2 (7)3 (11)1 (4) | 2 (7)5 (19)2 (7) | 0 (0)7 (26)0 (0) | 0 (0)8 (30)0 (0) |
| PIAtazanavirFosamprenavirIndinavirLopinavir/r NelfinavirRitonavir\*SaquinavirTipranavir | 4 (14) 7 (25)2 (7)16 (57)0 (0)8 (29)1 (4)0 (0) |  6 (21) 7 (25) 2 (7) 16 (57) 1 (4)11 (39) 1 (4) 2 (7) | 4 (15)5 (19)3 (11)10 (37)1 (4)8 (30)1 (4)0 (0) | 7 (26)8 (30)3 (11)12 (44)1 (4)12 (44)2 (7)1 (4) | 7 (26)1 (4)1 (4)10 (37)0 (0)8 (30)4 (15)1 (4) | 8 (30)2 (7)2 (7)11 (41)0 (0)11 (41)5 (19)3 (11) |
| Fusion inhibitorEnfuvirtide | 0 (0) |  1 (4) | 0 (0) | 1 (4) | 0 (0) | 3 (11) |

All data are presented as N(%)

\*Excludes ritonavir used as pharmacokinetic enhancer.

OBR1, first on-study optimized background regimen; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI, non- nucleoside/nucleotide reverse transcriptase inhibitor; PI, protease inhibitor; /r, with ritonavir boost.